[
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-1",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#definitiongeneral364634",
    "clean_content": "Definition / general\n\n* Rare neuroendocrine neoplasm of pancreas with functional production of insulin"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-2",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#essentialfeatures364635",
    "clean_content": "Essential features\n\n* Tumor secretes insulin (analogous to beta cell production in normal pancreatic islets) and thus clinical hyperinsulinemic hypoglycemia is required for this diagnosis* Majority of insulinomas are small (< 2 cm) and benign* Multiple insulinomas associated with multiple endocrine neoplasia type 1 (MEN1) syndrome"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-3",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#terminology364636",
    "clean_content": "Terminology\n\n* Beta cell tumor"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-4",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#icdcoding364637",
    "clean_content": "ICD coding\n\n* ICD-O: [8151/3](https://apps.who.int/iris/bitstream/handle/10665/96612/9789241548496_eng.pdf?sequence=1#page=66) - insulinoma, malignant* ICD-10:\n    + [C25.4](https://www.icd10data.com/ICD10CM/Codes/C00-D49/C15-C26/C25-/C25.4) - malignant neoplasm of endocrine pancreas+ [D13.7](https://www.icd10data.com/ICD10CM/Codes/C00-D49/D10-D36/D13-/D13.7) - benign neoplasm of endocrine pancreas+ [D37.8](https://www.icd10data.com/ICD10CM/Codes/C00-D49/D37-D48/D37-/D37.8) - neoplasm of uncertain behavior of other specified digestive organs* ICD-11: [2C10.1](https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1421495979) **& XH3UK0** - neuroendocrine neoplasms of pancreas & insulinoma, malignant"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-5",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#epidemiology364638",
    "clean_content": "Epidemiology\n\n* Usually seen in older adults* More common in females ([Ann Surg 2008;247:165](18156937))* Overall most common functioning pancreatic neuroendocrine neoplasm ([J Gastroenterol 2015;50:58](24499825))* Majority are benign; 5 - 10% are malignant ([Best Pract Res Clin Gastroenterol 2005;19:783](16253900))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-6",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#sites364639",
    "clean_content": "Sites\n\n* Pancreas, evenly distributed ([Pancreas 2014;43:675](24921202), [J Hepatobiliary Pancreat Sci 2019;26:383](31211879))* Extrapancreatic sites, such as duodenum or hilum of the spleen, are exceedingly rare ([J Hepatobiliary Pancreat Sci 2019;26:383](31211879))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-7",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#pathophysiology364640",
    "clean_content": "Pathophysiology\n\n* Unknown"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-8",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Etiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#etiology364641",
    "clean_content": "Etiology\n\n* Mostly sporadic; familial cases are associated with *MEN1* or *MAFA* germline mutations ([Endocr J 2012;59:859](22785103), [Proc Natl Acad Sci U S A 2018;115:1027](29339498))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-9",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#clinicalfeatures364642",
    "clean_content": "Clinical features\n\n* Whipple triad: symptoms of hypoglycemia (stupor, confusion, loss of consciousness), glucose < 45 mg/dL, symptoms relieved by glucose or symptoms caused by fasting or exercise* 10 - 15% associated with [MEN1 syndrome](https://www.pathologyoutlines.com/topic/pancreasMEN1.html); age < 20 years is suggestive of MEN1 (usually multiple tumors are seen) ([Endocr J 2012;59:859](22785103), [Best Pract Res Clin Gastroenterol 2005;19:783](16253900))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-10",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#diagnosis364643",
    "clean_content": "Diagnosis\n\n* Clinical diagnosis with demonstration of hyperinsulinemic hypoglycemia* 72 hour fast is the gold standard for diagnosis ([Endocrinol Metab Clin North Am 1999;28:519](10500929))* Imaging based modalities such as CT, ultrasound, MRI, PET or radiolabeled scintigraphy ([Neuroendocrinology 2009;90:167](19077417), [Best Pract Res Clin Endocrinol Metab 2005;19:311](15763703), [J Clin Endocrinol Metab 2009;94:4398](19820010))* Arteriography was once the gold standard but has been obviated by other, less invasive, modalities and generally is restricted for difficult cases; transhepatic portal venous sampling and selective arterial calcium stimulation with venous sampling are additional more invasive methods ([PLoS One 2019;14:e0224928](31743337))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-11",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#laboratory364644",
    "clean_content": "Laboratory\n\n* Demonstration of hyperinsulinemic hypoglycemia* Blood glucose ≤ 45 mg/dL, insulin ≥ 43 pmol/L, C peptide ≥ 200 pmol/L, no sulfonylurea in plasma ([Best Pract Res Clin Gastroenterol 2005;19:783](16253900))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-12",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#radiologydescription364645",
    "clean_content": "Radiology description\n\n* CT shows higher attenuation within the lesion than surrounding uninvolved pancreas in venous contrast enhancement phase* On ultrasound, the lesion is characterized by low echogenicity and hypervascularity* MRI and radiolabeled glucagon-like peptide 1 receptor (GLP-1R) scintigraphy has been used to localize small insulinomas ([J Clin Endocrinol Metab 2009;94:4398](19820010))* Reference: [Neuroendocrinology 2009;90:167](19077417)"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-13",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#radiologyimages364646",
    "clean_content": "Radiology images\n\nContributed by Irene Y. Chen, M.D.  \n\n[![CT abdomen](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaRadChen1.JPG)](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaRadChen1.JPG)\n \n[![CT abdomen](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaRadChen2.JPG)](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaRadChen2.JPG)\n\nCT abdomen\n\n[![MRI abdomen](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaRadChen3.JPG)](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaRadChen3.JPG)\n\nMRI abdomen"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-14",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Prognostic factors",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#prognosticfactors364647",
    "clean_content": "Prognostic factors\n\n* Stage and grade are important prognostic factors ([Neoplasma 2015;62:484](25866230))* Increased risk for metastasis and reduced survival in the following:\n    + Tumor ≥ 2 cm ([Neoplasma 2015;62:484](25866230), [Endocr Pathol 2020;31:108](32103422))+ ARX immunohistochemical (IHC) protein expression ([Endocr Pathol 2020;31:108](32103422))+ Loss of DAXX or ATRX by IHC stain and alternative lengthening of telomeres (ALT) ([Gastroenterology 2014;146:453](24148618), [Endocr Pathol 2020;31:108](32103422))* High Ki67 labeling index and high mitotic count are unfavorable prognostic factors (see [well differentiated neuroendocrine tumor](https://www.pathologyoutlines.com/topic/pancreasWDNET.html) for additional details on grading)* Insulinomas generally have a more favorable prognosis compared with nonfunctional tumors, as well as other functioning tumors ([Surg Pathol Clin 2016;9:595](27926362), [Front Med 2016;10:444](27757796))* Proteomic study revealed low tumor protein D52 expression as a strong independent prognostic factor for both recurrence free and overall disease related survival ([Mod Pathol 2015;28:69](24947143))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-15",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#casereports364648",
    "clean_content": "Case reports\n\n* 20 year old slender, lean man complained of increased hunger, tremor and frequent seizures with worsening symptoms for 4 months ([Cureus 2022;14:e23414](35475064))* 32 year old woman with long history of prolactinoma and secondary amenorrhea presented with hypoglycemia ([BMC Endocr Disord 2022;22:108](35448982))* 50 year old man transiently lost consciousness while piloting a helicopter rescue ([Med Lav 2022;113:e2022007](35226655))* 83 year old woman with recurrent episodes of delirium occurring overnight, associated with hypoglycemia ([Age Ageing 2022;51:afac055](35305086))* 84 year old nondiabetic woman presented with recurrent falls and hypoglycemic episodes ([Clin Med (Lond) 2022;22:90](35078802))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-16",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#treatment364649",
    "clean_content": "Treatment\n\n* Definitive surgical resection, enucleation is preferred if possible ([J Laparoendosc Adv Surg Tech A 2022 Apr 19 [Epub ahead of print]](35446126))* Symptomatic control with somatostatin analogs (octreotide) ([Neoplasma 2015;62:484](25866230))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-17",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#grossdescription364650",
    "clean_content": "Gross description\n\n* Most commonly a solitary, well delineated lesion with tan-yellow homogenous cut surface, with or without hemorrhage ([Surg Pathol Clin 2016;9:595](27926362))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-18",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#grossimages364651",
    "clean_content": "Gross images\n\nContributed by Irene Y. Chen, M.D. and Dennis R. Dening, PA (ASCP)  \n\n[![Pancreatic head tumor](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaGrossChen1.jpg)](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaGrossChen1.jpg)\n\nPancreatic head tumor\n\n[![Pancreatic tail tumor](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaGrossChen2.jpg)](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaGrossChen2.jpg)\n\nPancreatic tail tumor"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-19",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#microscopichistologicdescription364652",
    "clean_content": "Microscopic (histologic) description\n\n* Trabecular, nested, gyriform or solid architecture* Monotonous cells demonstrating round nuclei with salt and pepper-like chromatin and abundant cytoplasm* Amyloid stromal deposition may be seen (nonspecific) ([Arch Pathol Lab Med 1978;102:227](206226), [Endocr Pathol 2021;32:318](32399832))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-20",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#microscopichistologicimages364653",
    "clean_content": "Microscopic (histologic) images\n\nContributed by Diana Agostini-Vulaj, D.O.  \n\n[![Nested pattern](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaMicroAgostini01.jpg)](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaMicroAgostini01.jpg)\n\nNested pattern\n\n[![Synaptophysin](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaMicroAgostini02.jpg)](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaMicroAgostini02.jpg)\n\nSynaptophysin\n\n[![Insulin](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaMicroAgostini03.jpg)](https://www.pathologyoutlines.com/imgau/pancreasinsulinomaMicroAgostini03.jpg)\n\nInsulin"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-21",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Cytology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#cytologydescription364654",
    "clean_content": "Cytology description\n\n* See [well differentiated neuroendocrine tumor](https://www.pathologyoutlines.com/topic/pancreasWDNET.html) and [neuroendocrine neoplasms - general](https://www.pathologyoutlines.com/topic/pancreaspen.html)"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-22",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#positivestains364655",
    "clean_content": "Positive stains\n\n* [Synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html), [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html), **ISL1**, [INSM1](https://www.pathologyoutlines.com/topic/stainsinsm1.html) ([Am J Surg Pathol 2013;37:399](23348208))* **Insulin** (positivity is not required for diagnosis), **proinsulin** (50%), **amylin, islet amyloid polypeptide** ([Am J Surg Pathol 2013;37:399](23348208))* **PDX1** (beta cell marker) ([Endocr Pathol 2020;31:108](32103422)):\n      + Positive in indolent insulinoma; variable staining pattern in aggressive insulinoma* **ARX** (alpha cell marker) ([Endocr Pathol 2020;31:108](32103422)):\n        + Negative in indolent insulinoma; positive in aggressive insulinoma"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-23",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Negative stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#negativestains364656",
    "clean_content": "Negative stains\n\n* [Beta catenin](https://www.pathologyoutlines.com/topic/stainsbetacatenin.html) (normal membranous expression)* **PDX1** (beta cell marker) ([Endocr Pathol 2020;31:108](32103422)):\n    + Positive in indolent insulinoma; variable staining pattern in aggressive insulinoma* **ARX** (alpha cell marker) ([Endocr Pathol 2020;31:108](32103422)):\n      + Negative in indolent insulinoma; positive in aggressive insulinoma"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-24",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Electron microscopy description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#electronmicroscopydescription364657",
    "clean_content": "Electron microscopy description\n\n* Round secretory granules with paracrystalline content (similar to granules seen in beta cells of normal pancreatic islets) ([Nouv Presse Med 1977;6:3713](203897))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-25",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Molecular / cytogenetics description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#molecularcytogeneticsdescription364658",
    "clean_content": "Molecular / cytogenetics description\n\n* *MEN1, DAXX, ATRX, PTEN* and *TSC2* mutations as those seen in PanNET, are rare in insulinoma ([J Hepatobiliary Pancreat Sci 2019;26:383](31211879))* A subset (30%) showed recurrent p.T372R mutation in *YY1* gene ([Nat Commun 2013;4:2810](24326773), [J Clin Endocrinol Metab 2015;100:E776](25763608))* A subset showed alternative lengthening of telomere phenotype, loss of *DAXX / ATRX* and loss of *CDKN2A*, which is associated with metastatic disease and closely related to PanNET ([Endocr Pathol 2020;31:108](32103422))"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-26",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#samplepathologyreport364659",
    "clean_content": "Sample pathology report\n\n* Pancreas, distal pancreatectomy:\n  + Well differentiated neuroendocrine tumor, WHO grade \\_\\_, functional, clinically consistent with insulinoma"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-27",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#differentialdiagnosis364660",
    "clean_content": "Differential diagnosis\n\n* **Noninsulin secreting pancreatic neuroendocrine tumor** (see [well differentiated neuroendocrine tumor](https://www.pathologyoutlines.com/topic/pancreasWDNET.html) and [neuroendocrine neoplasms - general](https://www.pathologyoutlines.com/topic/pancreaspen.html)):\n  + Does not demonstrate clinical hyperinsulinemic hypoglycemia (i.e., are nonfunctional)+ Histologic features are essentially identical* [Solid pseudopapillary neoplasm](https://www.pathologyoutlines.com/topic/pancreassolidpseudo.html):\n    + Usually seen in young females+ No associated clinical syndrome of hyperinsulinemic hypoglycemia+ Pseudopapillae formation+ Positive nuclear [beta catenin](https://www.pathologyoutlines.com/topic/stainsbetacatenin.html)"
  },
  {
    "id": "insulinoma-beta-cell-tumor_41167_1750166973.txt-28",
    "source_document": "insulinoma-beta-cell-tumor_41167_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Additional references",
    "url": "https://www.pathologyoutlines.com/topic/pancreasinsulinoma.html#additionalreferences364661",
    "clean_content": "Additional references\n\n* [WHO Classification of Tumours Editorial Board: Digestive System Tumours, 5th Edition, 2019](https://www.amazon.com/exec/obidos/ASIN/9283244990/pathologyoutl-20), [WHO Classification of Tumours Editorial Board: Endocrine and Neuroendocrine Tumours, 5th Edition, 2025](https://www.amazon.com/exec/obidos/ASIN/9283245245/pathologyoutl-20)"
  }
]